Biology, clinical characteristics, and management of adrenocortical tumors in children

Pediatric Blood and Cancer

Volumn 45, Issue 3, 2005, Pages 265-273

  Rodriguez Galindo, Carlos ^a,b   Figueiredo, Bonald C ^c   Zambetti, Gerard P ^a,b   Ribeiro, Raul C ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Adrenocortical carcinoma; Adrenocortical tumors; Children; p53 mutations

Indexed keywords

CISPLATIN; MITOTANE; PROTEIN P53;

ADOLESCENT; ADRENAL CORTEX TUMOR; AGE; BRAZIL; CANCER INCIDENCE; CANCER STAGING; CHILD; CHILDHOOD CANCER; CLINICAL FEATURE; DISEASE PREDISPOSITION; GENE MUTATION; HORMONE SYNTHESIS; HUMAN; INOPERABLE CANCER; METASTASIS; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; RARE DISEASE; REVIEW; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR VOLUME; VIRILIZATION;

ADOLESCENT; ADRENAL CORTEX NEOPLASMS; ANTINEOPLASTIC AGENTS, HORMONAL; CHILD; CHILD, PRESCHOOL; GENES, P53; HUMANS; INFANT; MITOTANE; MUTATION; NEOPLASM STAGING; RESEARCH; SURVIVAL RATE;

EID: 23044499816     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20318     Document Type: Review

References (83)

1. Bernstein L, Gurney JG. Carcinomas and other malignant epithelial neoplasms. In: Ries LAG, Smith MA, Gurney JG , et al., editors. Cancer and survival among children and adolescents: United States SEER program 1975-1995 Bethesda, MD: National Cancer Institute, SEER program; 1999. pp 139-147.
2. Ribeiro RC, Sandrini F, Figueiredo B, et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci USA 2001;98: 9330-9335.
3. Wooten MD, King DK. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 1993;72:3145-3155.
4. Wagner J, Portwine C, Rabin K, et al. High frequency of germline p53 mutations in childhood adrenocortical cancer. J Natl Cancer Inst 1994;86:1707-1710.
5. Hoyme HE, Seaveer LH, Jones KL, et al. Isolated hemihyperplasia (Hemihypertrophy): Report of a prospective multicenter study of the incidence of neoplasia and review. Am J Med Genet 1998; 79:274-278.
6. Steenman M, Westerveld A, Mannens M. Genetics of Beckwith-Wiedeman Syndrome-Associated tumors: Common genetic pathways. Genes Chromosomes Cancer 2000;28:1-13.
7. Varan A, Unal S, Ruacan S, Vidinlisan S. Adrenocortical carcinoma associated with adrenogenital syndrome in a child. Med Pediatr Oncol 2000;35:88-90.
8. Kirschner LS. Signaling pathways in adrenocortical cancer. Ann NY Acad Sci 2002;968:222-239.
9. Light K, Jenkins PJ, Weber A, et al. Are activating mutations of the adrenocorticotropin receptor involved in adrenal cortical neoplasia? Life Sci 1995;56:1523-1527.
10. Latronico AC, Reincke M, Mendonca BB, et al. No evidence for oncogenic mutations in the adrenocorticotropin receptor gene in human adrenocortical neoplasms. J Clin Endocrinol Metab 1995; 80:875-877.
11. Kapas S, Hisnon JP. Inhibition of endothelin- and phorbol ester-stimulated tyrosine kinase activity by corticotropin in the rat adrenal zona glomerulosa. Biochem J 1996;313:867-872.
12. Reincke M, Mora P, Beuschlein F, et al. Deletion of the adrenocorticotropin receptor gene in human adrenocortical tumors: Implications for tumorigenesis. J Clin Endocrinol Metab 1997;82: 3054-3058.
13. Miller RW. Relation between cancer and congenital defects in man. N Engl J Med 1966;275:87-93.
14. Eggenschwiler J, Ludwid T, Ficher P, et al. Mouse mutant embryos overexpressingIGF-II exhibit phenotypic features of the Beckwith-Wiedeman and Simpson-Golabi-Behmel syndromes. Genes Dev 1997;11:3128-3142.
15. Ilvesmaki V, Kahri AI, Miettinen PJ, et al. Insulin-like growth factors (IGFs) and their receptors in adrenal tumors: High IGF-II expression in functional adrenocortical carcinomas. J Clin Endocrinol Metab 1993;77:852-858.
16. Boulle N, Logie A, Gicquel C, et al. Increased levels of insulin-like growth factor II (IGF-II) and IGF binding protein-2 are associated with malignancy in sporadic adrenocortical tumors. J Clin Endocrinol Metab 1998;83:1713-1720.
17. Gicquel C, Bertagna X, Schneid H, et al. Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. J Clin Endocrinol Metab 1994;78:1444-1453.
18. Weber MM, Auernhammer CJ, Kiess W, Engelhardt D. Insulin-like growth receptors in normal and tumorous adult human adrenocortical glands. Eur J Endocrinol 1997;136:296-303.
19. Weber MM, Fottner C, Wolf E. The role of the insulin-like growth factor system in adrenocortical tumorigenesis. Eur J Clin Invest 2000;30(suppl 3):69-75.
20. Weber MM, Fottner C, Schmidt P, et al. Postnatal overexpression of insulin-like growth factor II in transgenic mice is associated with adrenocortical hyperplasia and enhanced steroidogenesis. Endocrinology 1999;140:1537-1543.
21. Eguchi T, Tokuyama A, Tanaka Y, et al. Hypoglycemia associated with the production of insulin-like growth factor II in adrenocortical carcinoma. Intern Med 2001;40:759-763.
22. Kamio T, Shigematsu K, Sou H, Kawai K, Tsuchiyama H. Immunohistochemical expression of epidermal growth factor receptors in human adrenocortical carcinoma. Hum Pathol 1990; 21:277-282.
23. Sasano H, Suzuki T, Shizawa S, et al. Transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor expression in normal and diseased human adrenal cortex by immunohistochemistry and in situ hybridization. Mod Pathol 1994;7:741-746.
24. Birch J, Alston RD, McNally RJQ, et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 2001;20:4621-4628.
25. Kleihues P, Schäuble B, zur Hausen A, et al. Tumors associated with p53 germline mutations. A synopsis of 91 families. Am J Pathol 1997;150:1-13.
26. Varley JM, McGown G, Thorncroft M, et al. Are there low-penetrance TP53 alleles? Evidence from childhood adrenocortical tumors. Am J Hum Genet 1999;65:995-1006.
27. Reincke M, Karl M, Travis WH, et al. p53 mutations in human adrenocortical neoplasms: Immunohistochemical and molecular studies. J Clin Endocrinol Metab 1994;78:790-794.
28. DiGiammarino EL, Lee AS, Cadwell C, et al. A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nat Struct Biol 2001;9:12-16.
29. Dohna M, Reincke M, Mincheva A, et al. Adrenocortical carcinoma is characterized by a high frequency of chromosomal gains and high-level amplifications. Genes Chromosomes Cancer 2000;28:145-152.
30. Figueiredo BC, Stratakis CA, Sandrini R, et al. Comparative genomic hybridization analysis of adrenocortical tumors of childhood. J Clin Endocrinol Metab 1999;84:1116-1121.
31. Vassilopoulou-Sellin R, Schultz PN. Adrenocortical carcinoma: Clinical outcome at the end of the 20th century. Cancer 2001;92: 1113-1121.
32. Kendrick ML, Lloyd R, Erickson L, et al. Adrenocortical carcinoma: Surgical progress or status quo? Arch Surg 2001;136: 543-549.
33. Wajchenberg BL, Pereira MAA, Medonca BB, et al. Adrenocortical carcinoma: Clinical and laboratory observations. Cancer 2000;88:711-736.
34. Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol 1999;6:719-726.
35. Luton JP, Cerdas S, Billaud L, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990;322:1195-1201.
36. Crucitti F, Bellantone R, Ferrante A, et al. the Italian Registry for adrenal cortical carcinoma: Analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery 1996;119:161-170.
37. Icard P, Chapuis Y, Andreassian B, et al. Adrenocortical carcinoma in surgically treated patents: A retrospective study on 156 cases by the Frenc Association of Endocrine Surgery. Surgery 1992;112: 972-979.
38. Ribeiro RC, Sandrini Neto R, Schell MJ, et al. Adrenocortical carcinoma in children: A study of 40 cases. J Clin Oncol 1990;8: 67-74.
39. Ciftci AO, Senocak ME, Tanyel FC, et al. Adrenocortical tumors in children. J Pediatr Surg 2001;36:549-554.
40. Driver CP, Birch J, Gough DCS, Bruce J. Adrenal cortical tumors in childhood. Pediatr Hematol Oncol 1998;15:527-532.
41. Stojadinovic A, Ghossein RA, Hoos A, et al. Adrenocortical carcinoma: Clinical, morphologic, and molecular characterization. J Clin Oncol 2002;20:941-950.
42. Ribeiro J, Ribeiro RC, Fletcher BD. Imaging findings in pediatric adrenocortical carcinoma. Pediatr Radiol 2000;30: 45-51.
43. Kreissig R, Amthauer H, Krude H, et al. The use of FDG-PET and CT for the staging of adrenocortical carcinoma in children. Pediatr Radiol 2000;30:306.
44. Ahmed M, Al-Sugair A, Alarifi A, et al. Whole-body positron emission tomographic scanning in patients with adrenal cortical carcinoma. Comparison with conventional imaging procedures. Clin Nucl Med 2003;28:494-497.
45. Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol 1984;8:163-169.
46. Slooten HV, Schaberg A, Smeenk D, Moolenaar AJ. Morphologic characteristics of benign and malignant adrenocortical tumors. Cancer 1985;55:766-773.
47. Weiss LM, Medeiros LJ, Vickery AL. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 1989;13:202-206.
48. Harrison LE, Gaudin PB, Brennan MF. Pathologic features of prognostic significance for adrenocortical carcinoma after curative resection. Arch Surg 1999;134:181-185.
49. Erickson LA, Jin L, Sebo TJ, et al. Pathologic features and expression of insulin-like growth factor-2 in adrenocortical neoplasms. Endocr Pathol 2001;12:429-435.
50. Wieneke JA, Thompson LDR, Heffess CS. Adrenal cortical neoplasms in the pediatric population: A clinicopathologic and immunophenotypic analysis of 83 patients. An J Surg Pathol 2003;27:867-881.
51. Sandrini R, Ribeiro RC, DeLacerda L. Childhood adrenocortical tumors. J Clin Endocrinol Metab 1997;7:2027-2031.
52. Bugg MF, Ribeiro RC, Roberson PK, et al. Correlation of pathologic features with clinical outcome in pediatric adrenocortical neoplasia. Am J Clin Pathol 1994;101:625-629.
53. Michalkiewicz E, Sandrini R, Figueiredo B , et al. Clinical and outcome characteristics of children with adrenocortical tumors. An analysis of 254 cases from the International Pediatric Adrenocortical Tumor Registry. J Clin Oncol 2004;22:838-845.
54. Michalkiewicz EL, Sandrini R, Bugg MF, et al. Clinical characteristics of small functioning adrenocortical tumors in children. Med Pediatr Oncol 1997;28:175-178.
55. Haak HR, Hermans J, van de Velde CJ, et al. Optimal treatment of adrenocortical carcinoma with mitotane: Results in a consecutive series of 96 patients. Br J Cancer 1994;69:947-951.
56. Bellantone R, Ferrante A, Boscherini M, et al. Role of reoperation in recurrence of adrenal cortical carcinoma: Results from 188 cases collected in the Italian national registry for adrenal cortical carcinoma. Surgery 1997;122:1212-1218.
57. Leung LYJ, Leung WY, Chan KF, et al. Ruptured adrenocortical carcinoma as a cause of paediatric acute abdomen. Pediatr Surg Int 2002;18:730-732.
58. Kardar AH. Rupture of adrenal carcinoma after biopsy. J Urol 2001;166:984.
59. Van Slooten H, Moolenaar AJ, Van Seters AP, Smeenk D. The treatment of adrenocortical carcinoma with o,p'-DDD: Prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol 1984;20:47-53.
60. Baudin E, Pellegriti G, Bonnay M, et al. Impact of monitoring plasma 1,1-Dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 2001;92:1385-1392.
61. Ilias I, Alevizaki M, Philippou G, et al. Sustained remission of metastatic adrenal carcinoma during long-term administration of low-dose mitotane. J Endocrinol Invest 2001;24:532-535.
62. Vassilopoulou-Sellin R, Guinee VF, Klein MJ, et al. Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer 1993;71:3119-3123.
63. Coelho Netto AS, Wajchenberg BL, Ravaglia C, et al. Treatment of adrenocortical cancer with o,p'-DDD. Ann Intern Med 1963; 59:74-78.
64. Fisher DA, Panos TC, Melby JC. Therapy of adrenocortical cancer with o-p'-DDD in two children. J Clin Endocrinol Metab 1963;23: 218-221.
65. Ostuni JA, Roginsky MS. Metastatic adrenal cortical carcinoma: Documented cure with combined chemotherapy. Arch Intern Med 1975;135:1257-1258.
66. Dickstein G, Shechner C, Arad E, et al. Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma? J Clin Endocrinol Metab 1998;83:3100-3103.
67. Terzolo M, Pia A, Berruti A, et al. Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. J Clin Endocrinol Metab 2000;85:2234-2238.
68. Robinson BG, Hales IB, Henniker AJ, et al. The effect of o,p'-DDD on adrenal steroid replacement therapy requirements. Clin Endocrinol 1987;27:437-444.
69. Van Seters AP, Moolenaar AJ. Mitotane increases the blood levels of hormone-binding proteins. Acta Endocrinol 1991;124:526-533.
70. Chun HG, Yogoda A, Kemeny N. Cisplatinum for adrenal cortical carcinoma. Cancer Treat Rep 1983;76:513-514.
71. Van Slooten H, Van Oosterom AT. CAP (cyclophosphamide, doxorubicin and cisplatinum) regimen in adrenal cortical carcinoma. Cancer Treat Rep 1983;67:377-379.
72. Schlumberger M, Brugieres L, Gicquel C , et al. Fluorouracil, doxorubicin and cisplatin as treatment for adrenal cortical carcinoma. Cancer 1991;67:2997-3000.
73. Williamson SK, Lew D, Miller GJ, et al. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma. Cancer 2000;88:1159-1165.
74. Hovi L, Wikström S, Vettenrante K, et al. Adrenocortical carcinoma in children: A role for etoposide and cisplatin adjuvant therapy? Preliminary report. Med Pediatr Oncol 2003;40:324-326.
75. Abraham J, Bakke S, Rutt A, et al. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma. Cancer 2002;94:2333-2343.
76. Flynn SD, Murren JR, Kirby WM, et al. P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma. Surgery 1992;112:981-986.
77. Haak HR, Van Seters AP, Moolenaar AJ, Fleuren GJ. Expression of P-glycoprotein in relation to clinical manifestation, treatment and prognosis of adrenocortical cancer. Eur J Cancer 1993;29A:1036-1038.
78. Bates SE, Shieh CY, Mickley LA, et al. Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (MDR-1/P-Glycoprotein) which is also expressed by adrenocortical carcinoma. J Clin Endocrinol Metab 1991;73: 18-29.
79. Bonacci R, Gigliotti A, Baudin E, et al. Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma. Br J Cancer 1998;78:546-549.
80. Berruti A, Terzolo M, Pia A, et al. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Cancer 1998;83:2194-2200.
81. Wood BJ, Abraham J, Hvizda JL, et al. Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases. Cancer 2003;97:554-560.
82. Lee JE, Berger DH, el-Naggar AK, et al. Surgical management, DNA content, and patient survival in adrenal cortical carcinoma. Surgery 1995;118:1090-1098.
83. James LA, Kelsey AM, Birch JM, et al. Highly consistent genetic alterations in childhood adrenocortical tumours detected by comparative genomic hybridization. Br J Cancer 1999;81:300-304.